Aiming to provide a consistent regulatory framework for drug sponsors developing digital health tools, the US Food and Drug Administration (FDA) has finalized guidance outlining how prescription drug-related software and companion mobile applications should be reviewed, labeled, and submitted to the agency.
Published in the Federal Register on October 21,